Drugs / Allocetra-OTS
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06208241 | Jul 2023 → Sep 2026 expected | osteoarthritis, knee | Amir Oron | Active not recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04513470 | Aug 2020 → Jan 2021 | COVID-19 | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 1 | NCT03925857 | Jan → Dec 2019 | infectious disease with sepsis | Enlivex Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05581719 | Nov 2022 → Apr 2024 | peritoneal carcinomatosis | Enlivex Therapeutics RDO Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05431907 | Jun 2022 → Mar 2024 | peritoneal carcinomatosis | Enlivex Therapeutics RDO Ltd. | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04922957 | Sep 2021 → Apr 2022 | COVID-19 | Enlivex Therapeutics Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT04612413 | Nov 2020 → Jan 2024 | acute cholecystitis, infectious disease with sepsis, pneumonia, urinary tract infection | Enlivex Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04590053 | Oct 2020 → Feb 2021 | COVID-19 | Hadassah Medical Organization | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04659304 Comparator | Dec 2021 → Sep 2022 | COVID-19 | Enlivex Therapeutics Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allocetra-OTS | “The primary aim of this phase IB study was to determine the safety profile of Allocetra™-OTS (early apoptotic cell) infusion in subjects presenting to the emergency room with sepsis.” PMID 34659208 ↗ Sep 202110“apoptotic cells (Allocetra™-OTS, Enlivex Therapeutics), a cellular immunomodulatory therapy that reprograms macrophages to reduce hyper-inflammatory response severity.” PMID 37600829 ↗ Aug 2023 |
| Modality | Cell therapy | “The study drug, Allocetra-OTS is a cell-based therapeutic composed of donor apoptotic cells.” NCT03925857 ↗ |
| Route | Intravenous | “Subjects will receive single intravenous (IV) administration of investigational product” NCT04513470 ↗ |